
Parmax Pharma Limited — Investor Relations & Filings
Parmax Pharma Limited specializes in the development, manufacturing, and distribution of a broad spectrum of pharmaceutical formulations. The company’s product range encompasses various delivery systems, including solid orals like tablets and capsules, as well as liquid preparations and topical ointments. Its therapeutic focus spans several categories, such as anti-infectives, analgesics, gastrointestinal agents, and respiratory medications. The organization maintains a commitment to stringent quality control measures and adheres to Good Manufacturing Practices (GMP) to ensure product safety and therapeutic effectiveness. By leveraging advanced production facilities and a comprehensive distribution infrastructure, the company provides healthcare solutions across multiple markets. Its core operations prioritize formulation research and the scaling of manufacturing processes to meet diverse clinical requirements.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| Reschedule of Boar Meeting and Outcome of Board Meeting | 2026-06-03 | English | |
| Proceedings of EGM held on May 27, 2026 | 2026-05-31 | English | |
| Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/06/2026 ,inter alia, to consider and approve audited financial results for .... | 2026-05-30 | English | |
| Scrutinizer Report | 2026-05-28 | English | |
| Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve audited financial results of .... | 2026-05-27 | English |
Browse filings by year
1 year| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
5 filings
| |||||
| 47949135 | Reschedule of Boar Meeting and Outcome of Board Meeting | 2026-06-03 | English | ||
| 47907675 | Proceedings of EGM held on May 27, 2026 | 2026-05-31 | English | ||
| 47904229 | Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/06/2026 ,inter alia, to consider and approve audited financial results for .... | 2026-05-30 | English | ||
| 47864949 | Scrutinizer Report | 2026-05-28 | English | ||
| 47802267 | Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve audited financial results of .... | 2026-05-27 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
CATALYST PHARMACEUTICALS, INC.
Biopharmaceutical company commercializing drugs for rare ne…
|
CPRX | US | Manufacturing |
|
cbdMD, Inc.
Producer and distributor of health and wellness CBD product…
|
YCBD | US | Manufacturing |
|
CCSB
Specialized manufacturer of APIs for oncology, antifungal, …
|
1762 | TW | Manufacturing |
|
CDT Equity Inc.
A clinical-stage biopharmaceutical firm advancing assets fo…
|
CDT | US | Manufacturing |
|
Ceapro Inc.
Develops and commercializes natural active ingredients deri…
|
CZO | CA | Manufacturing |
|
CELADON PHARMACEUTICALS PLC
Researches, cultivates, and manufactures cannabinoid-based …
|
CEL | GB | Manufacturing |
|
Celemics, Inc.
Develops NGS target enrichment solutions for research and c…
|
331920 | KR | Manufacturing |
|
Cellbion Co., Ltd
Develops radiopharmaceuticals and radioligand therapies for…
|
308430 | KR | Manufacturing |
|
CELL BIOTECH CO ., LTD
Develops and manufactures probiotic solutions using patente…
|
049960 | KR | Manufacturing |
|
Celldex Therapeutics, Inc.
Develops antibody-based immunotherapies for severe inflamma…
|
CLDX | US | Manufacturing |
Parmax Pharma Limited via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/60762/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=60762 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=60762 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=60762 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 60762}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Parmax Pharma Limited (id: 60762)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.